CEO Robert Michael stated that "AbbVie's business continues to perform above our expectations. We delivered another excellent quarter, including strong financial results, pipeline advancement across ...

GSK shares rose to the top of the FTSE 100 leader board after the drugmaker raised its 2025 guidance on the back of a strong third-quarter performance. The earnings were the last to be presented by ...

Pfizer's stock has likely bottomed and shows strong technical and fundamental indicators, including a "Golden Cross" and robust cost reduction plans. The company's promising pipeline, including weight ...

Incyte (NASDAQ:INCY) Corporation, a biopharmaceutical company specializing in proprietary therapeutics with a market capitalization of $14 billion, finds itself at a critical juncture as it navigates ...

Arcutis Biotherapeutics’ (ARQT) breakthroughs in the medical dermatology field have the company posting notable performance. The company’s product launch of Zoryve helped to drive Q3 earnings beyond ...

AvalonBay Communities finished 2024 with a strong development pipeline that positions the multifamily owner for further growth. The Arlington, Va.-based real estate investment trust (REIT) recorded ...

OPKO Health has improved its financial position by selling most of BioReference, reducing cash burn, and strengthening its balance sheet. Ngenla's profit share with Pfizer has underperformed ...

Except for the historical information contained herein, the matters discussed in this release consist of forward-looking statements that involve certain risks and uncertainties that could cause actual ...

Immunocore Holdings PLC (NASDAQ:IMCR) is one of the best 52-week high stocks to buy right now. Immunocore Holdings PLC (NASDAQ:IMCR) commands a consensus Moderate Buy rating from 9 Wall Street ...

Sino Biopharmaceutical, or SBP, is one of the four "big pharma" drugmakers in China, and operates in a fast-growing and rapidly changing environment. Drug manufacturing is growing faster than GDP, and ...

The $571 million Signia by Hilton convention center hotel is about one-quarter complete. (IBJ photo/Chad Williams) Five years out from the pandemic, the Indianapolis tourism industry has bounced back ...